The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results.
Merkel cell carcinoma
Merkel cell polyomavirus
Neuroendocrine tumor
Skin cancer
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
30
04
2023
accepted:
01
06
2023
medline:
16
8
2023
pubmed:
14
6
2023
entrez:
13
6
2023
Statut:
ppublish
Résumé
Even in the novel immunotherapy era, Merkel cell carcinoma (MCC) remains challenging in its treatment. Apart from Merkel cell polyomavirus (MCPyV) associated MCC, this cancer is linked in about 20% of cases to ultraviolet-induced mutational burden frequently causing aberrations in Notch and PI3K/AKT/mTOR signalling pathways. The recently developed agent GP-2250 is capable to inhibit growth of cells of different cancers, including pancreatic neuroendocrine tumors. The objective of the present study was to investigate the effects of GP-2250 on MCPyV-negative MCC cells. Methods We employed three cell lines (MCC13, MCC14.2, MCC26) which were exposed to different GP-2250doses. GP-2250's effects on cell viability, proliferation, and migration were evaluated by means of MTT, BrdU, and scratch assays, respectively. Flow cytometry was performed for the evaluation of apoptosis and necrosis. Western blotting was implemented for the determination of AKT, mTOR, STAT3, and Notch1 protein expression. Cell viability, proliferation, and migration decreased with increasing GP-2250 doses. Flow cytometry revealed a dose response to GP-2250 in all three MCC cell lines. While the viable fraction decreased, the share of necrotic and in a smaller amount the apoptotic cells increased. Regarding Notch1, AKT, mTOR, and STAT3 expression a comparatively time- and dose-dependent decrease of protein expression in the MCC13 and MCC26 cell lines was observed. By contrast, Notch1, AKT, mTOR, and STAT3 expression in MCC14.2 was scarcely altered or even increased by the three dosages of GP-2250 applied. The present study indicates GP-2250 having anti-neoplastic effects in MCPyV-negative tumor cells in regard to viability, proliferation, and migration. Moreover, the substance is capable of downregulating protein expression of aberrant tumorigenic pathways in MCPyV-negative MCC cells.
Sections du résumé
BACKGROUND
BACKGROUND
Even in the novel immunotherapy era, Merkel cell carcinoma (MCC) remains challenging in its treatment. Apart from Merkel cell polyomavirus (MCPyV) associated MCC, this cancer is linked in about 20% of cases to ultraviolet-induced mutational burden frequently causing aberrations in Notch and PI3K/AKT/mTOR signalling pathways. The recently developed agent GP-2250 is capable to inhibit growth of cells of different cancers, including pancreatic neuroendocrine tumors. The objective of the present study was to investigate the effects of GP-2250 on MCPyV-negative MCC cells.
METHODS
METHODS
Methods We employed three cell lines (MCC13, MCC14.2, MCC26) which were exposed to different GP-2250doses. GP-2250's effects on cell viability, proliferation, and migration were evaluated by means of MTT, BrdU, and scratch assays, respectively. Flow cytometry was performed for the evaluation of apoptosis and necrosis. Western blotting was implemented for the determination of AKT, mTOR, STAT3, and Notch1 protein expression.
RESULTS
RESULTS
Cell viability, proliferation, and migration decreased with increasing GP-2250 doses. Flow cytometry revealed a dose response to GP-2250 in all three MCC cell lines. While the viable fraction decreased, the share of necrotic and in a smaller amount the apoptotic cells increased. Regarding Notch1, AKT, mTOR, and STAT3 expression a comparatively time- and dose-dependent decrease of protein expression in the MCC13 and MCC26 cell lines was observed. By contrast, Notch1, AKT, mTOR, and STAT3 expression in MCC14.2 was scarcely altered or even increased by the three dosages of GP-2250 applied.
CONCLUSIONS
CONCLUSIONS
The present study indicates GP-2250 having anti-neoplastic effects in MCPyV-negative tumor cells in regard to viability, proliferation, and migration. Moreover, the substance is capable of downregulating protein expression of aberrant tumorigenic pathways in MCPyV-negative MCC cells.
Identifiants
pubmed: 37311987
doi: 10.1007/s00432-023-04960-3
pii: 10.1007/s00432-023-04960-3
pmc: PMC10423113
doi:
Substances chimiques
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
TOR Serine-Threonine Kinases
EC 2.7.11.1
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10831-10840Informations de copyright
© 2023. The Author(s).
Références
Biochem J. 2020 Jul 31;477(14):2721-2733
pubmed: 32639530
Clin Transl Oncol. 2013 Mar;15(3):167-72
pubmed: 22911551
Cancer Lett. 2014 Mar 28;344(2):272-281
pubmed: 24262658
Cancers (Basel). 2021 Feb 05;13(4):
pubmed: 33562873
Oncotarget. 2016 Jan 19;7(3):3403-15
pubmed: 26655088
Mod Pathol. 2009 Jul;22(7):959-68
pubmed: 19396152
BMC Cancer. 2017 Mar 24;17(1):216
pubmed: 28340556
J Cancer Res Clin Oncol. 2023 Sep;149(11):9071-9083
pubmed: 37171614
JAMA Netw Open. 2023 Jan 3;6(1):e2249674
pubmed: 36602798
Int J Mol Sci. 2021 Jun 11;22(12):
pubmed: 34208339
Cancer Res. 2015 Dec 15;75(24):5228-34
pubmed: 26627015
Tumour Virus Res. 2022 Dec;14:200244
pubmed: 36007768
Int J Mol Sci. 2022 Jun 30;23(13):
pubmed: 35806313
Nat Rev Dis Primers. 2017 Oct 26;3:17077
pubmed: 29072302
Cancer Res. 2015 Sep 15;75(18):3720-3727
pubmed: 26238782
Hum Pathol. 2015 Feb;46(2):210-6
pubmed: 25466966
Cancer Sci. 2022 Jan;113(1):251-260
pubmed: 34724284
Clin Exp Dermatol. 2021 Dec;46(8):1551-1554
pubmed: 34115902
J Dtsch Dermatol Ges. 2023 Mar;21(3):305-320
pubmed: 36929552
J Invest Dermatol. 2021 Jul;141(7):1675-1686.e4
pubmed: 33600825
Curr Opin Oncol. 2012 Mar;24(2):141-9
pubmed: 22234254
Anticancer Res. 2019 Jan;39(1):319-329
pubmed: 30591475
Oncotarget. 2017 Jul 13;8(45):79731-79741
pubmed: 29108353
Cancers (Basel). 2022 May 29;14(11):
pubmed: 35681665
J Natl Cancer Inst. 2009 Jul 1;101(13):938-45
pubmed: 19535775